We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Atypical hemolytic uremic syndrome is a ...

Left untreated, PNH could cause death in about half of patients within 10 years of diagnosis. The primary cause of PNH-related mortality is thromboembolic events. A host of anti-complement strategies, ...

Atypical haemolytic uremic syndrome (aHUS) is an uncommon, yet potentially life‐threatening disorder predominantly characterised by dysregulation of the alternative complement pathway. Unlike the more ...

"Atypical Hemolytic Uremic Syndrome Pipeline"Following the success of terminal complement inhibitors like eculizumab and ravulizumab, the therapeutic focus in 2025 has shifted towards developing ...

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, severe, and potentially life-threatening condition. Treatments targeting the complement pathway have revolutionized its management but have ...

Please provide your email address to receive an email when new articles are posted on . Registry data showed efficacy of ravulizumab was similar to that of eculizumab. No unexpected adverse events ...

TSP-1 reduced C3 and C5 cleavage and formation of the membrane attack complex, attenuating complement-mediated injury in AAV models. Complement activation is a relevant driver in the pathomechanisms ...

- Provides opportunity to enhance treatment for PNH patients experiencing extravascular hemolysis (EVH), potential first-in-class C3 glomerulopathy (C3G) therapy & promising development platform for ...

Amyndas Pharmaceuticals S.A. is pleased to announce today that the Aplastic Anemia & MDS International Foundation (AA&MDSIF) is endorsing the clinical development of Amyndas' lead candidate AMY-101, ...

A research letter published in Blood Advances details the first clinical evidence of sustained hematologic remission for cold agglutinin disease (CAD) after sutimlimab treatment discontinuation.

Amyndas Pharmaceuticals S.A. is pleased to announce today that the Aplastic Anemia & MDS International Foundation (AA&MDSIF) is endorsing the clinical development of Amyndas' lead candidate AMY-101, ...